Abstract: A thermostable glycosidase enzymes derived from various Thermococcus, Staphylothermus and Pyrococcus organisms is disclosed. The enzymes are produced from native or recombinant host cells and can be utilized in the food processing industry, pharmaceutical industry and in the textile industry, detergent industry and in the baking industry.

Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.

Abstract: Methods to generate analogs of coenzyme A in vivo are disclosed. The methods to generate analogs of coenzyme A in a cell comprise reacting pantetheine or a derivative thereof with a reporter to form labeled pantetheine or a derivative thereof, contacting the cell with the labeled pantetheine or derivative thereof such that the labeled pantetheine or derivative thereof enters the cell, phosphorylating the labeled pantetheine or derivative thereof to form phosphopantetheine or a derivative thereof, adenylating the labeled phosphopantetheine or derivative thereof to form a labeled dephosphoCoenzyme A or derivative thereof, and phosphorylating the 3?-hydroxyl of the labeled dephosphoCoenzyme A or derivative thereof to form a labeled coenzyme A analog or derivative thereof.

Abstract: The present invention provides cellulase-containing dishwashing detergent compositions. The present invention also provides methods for the production of and use of such detergents. In addition, a spaghetti mix soil suitable for testing dishwashing detergents is also provided.

Abstract: The present invention relates to compounds that are substrates for an enzyme, and upon reaction with the enzyme provide a detectable response, such as an optically detectable response. In particular, the compounds have utility in detecting the presence of a ?-lactamase in a sample. In addition to the compounds, methods are disclosed for analyzing a sample for the presence of a ?-lactmase, for example, as an indicator of expression of a nucleic acid sequence including a sequence coding for a ?-lactmase. Kits are disclosed that include the disclosed compounds and additional components, for example, cells, antibodies, a ?-lactmase or instructions for using the components in an assay.

Abstract: The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.

Abstract: Biomarkers for stroke and methods for their detection are disclosed. In one aspect, the present application discloses biomarkers for the diagnosis of stroke in a subject. In another aspect, the application discloses a method for the diagnosis of stroke in a subject. The method comprises detection of stroke biomarkers in cerebrospinal fluid, blood, serum or PMBCs of a subject. Also disclosed is a kit for the detection of biomarkers for the diagnosis of stroke in a subject.

Abstract: This invention comprises the novel compounds of formula (I) wherein n, m, t, R1, R2, R3, R4, R5, L, Q, X, Y and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

Abstract: The invention relates to a method and a kit for the detection of Trichomonas infection by detecting N-acetyl-?-D-hexosaminidase activity. The invention also relates to a method and a kit for selective detection of presence of Trichomonas or Candida infection.

Abstract: Methods and kits for performing a two-phase optical assay for one or more than one analyte without intrinsic optical contrast in a sample are disclosed. The method requires use of a functionalized microparticle immobilized with two or more than functional components and an additional set of one or more than one functional component. The assay can be performed in one single container and does not need a wash step.

Abstract: The invention relates to detection and modulation of cytochrome c acetylation. The invention has diagnostic and therapeutic applications for neurodegenerative disorders and cancer.

Abstract: Provided herein are methods for identifying molecules capable of modulating SERCA, the SERCA-PLB complex or the microenvironment of the complex. An exemplary assay provided herein is fluorescence resonance energy transfer (FRET). Also provided herein are FRET assays that are optimized for high-throughput screening (HTS) for identifying small molecules that modulate SERCA or the SERCA-PLB complex. Further provided are kits for carrying out said methods for identifying molecules.

Abstract: Truncated fragments of the small fragment of ?-galactosidase are provided that have low affinity for the large fragment of ?-galactosidase and provide for robust signals when two fusion proteins are complexed due to the binding of the proteins to which the ?-galactosidase fragments are fused. The truncated fragments do not interfere with the complexing of the two proteins and allow for the two proteins to function and be responsive to candidate compounds that affect complex formation.

Abstract: The present invention relates to a swatch comprising a pH-indicator substance and a substrate for an enzyme for testing the washing performance of the enzyme, e.g. an enzyme for use in detergent compositions.

Abstract: Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer.

Abstract: Methods and devices are provided for the rapid and specific detection of target microorganisms, cells, and the like. In one embodiment, the methods involve contacting a target microorganism (e.g., in a sample) with a permeabilization reagent that selectively permeabilizes or lyses the microorganism; contacting the selectively permeabilized microorganism with a detection reagent that is taken into the selectively permeabilized organism or that contacts metabolites or enzymes released by the selectively permeabilized microorganism, where the detection reagent produces a signal in the presence of said metabolites or enzymes; and detecting a signal produced by the detection reagent in the presence of the metabolites or enzymes wherein the strength of the signal indicates the presence and/or amount of the target microorganism in the sample.

Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsinlike activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Abstract: The disclosure relates to compounds and methods of inhibiting type three secretion system effector molecules, to methods of detecting compounds that inhibit Yops translocation, and to methods of treating or preventing infections by administering compounds described herein to a subject in need thereof.

Abstract: The subjects of the current invention are compounds, which exhibit arginase inhibiting activity (including difluoromethylornithine (DFMO) and L-norvaline, but not limited to them), and which can be used as therapeutically active agents for the treatment and prevention of depression and/or depression-related conditions. Other subjects of the present invention are the use of said arginase inhibiting compounds as therapeutically active agents for the manufacture of pharmaceutical compositions for human and veterinary application, pharmaceutical composition comprising said arginase inhibiting compound and a method for treatment and prevention of depression and/or depression-related conditions. Also, a method for identifying compounds suitable for use as therapeutically active agents for treatment and/or prevention of depression and/or depression-related conditions is disclosed.

Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (I) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.

Abstract: The present invention is directed to methods of modulating HSF1 activity comprising modifying the acetylation of the DNA binding domain of the HSF1.

Abstract: Methods and compositions for identification of candidate antigen-specific variable regions as well as generation of antibodies or antigen-binding fragments that could have desired antigen specificity are provided. For example, in certain aspects methods for determining amino acid sequences of serum antibody CDR and abundancy level are described. In some aspects, methods for determining nucleic acid sequences of antibody variable region sequences and frequency are provided. Furthermore, the invention provides methods for identification and generation of antibody or antigen-binding fragments that comprise highly-represented CDR.

Abstract: This invention is related to preparation of photosensitive ruthenium based aminoacid monomers and oligomers, aminoacid monomer-protein cross-linking using photo sensitat ion and conjugation on micro and nano-structures by ruthenium-chelate based monomers. Its vast range biotechnolgy applications of multifunctional, biocompatible, stabilE and specific micro and nanobio-conjugates, which will stand-alone or simultaneously enable (i) both purification and determination, (ii) both targeting and imaging and theranostics and (iii) catalysis and determination. The construction and method of preparation is applicable to silica materials, superparamagnetic particles, QDs, CNTs, Ag/Au nanoparticles and Au surfaces and polymeric materials. The photosensitive aminoacid monomer linkers can react via chemically and biocompatible to a lot of different micro and nano-surface and then to the protein when they act as a single-step cross-linking reaction using irradiation.

Abstract: The invention relates to a new method for measuring a calcium-dependent phospholipase A1 or A2 enzymatic activity in a sample, comprising the following steps: a) contacting said sample with a solid phase coated with a fluorochrome-labelled phospholipase A1 or A2 substrate, wherein the molecular coverage is in the range 8 to 30 fluorochrome-labelled phospholipase A1 or A2 substrate molecules/nm2 in conditions where calcium-dependent phospholipase A1 or A2 enzymatic activity is blocked. b) reading the fluorescence emission overtime c) adding a solution to initiate calcium-dependent phospholipase A1 or A2 enzymatic activity d) reading the fluorescence emission overtime, and kits for carrying out said method.

Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Abstract: Among other things, the present disclosure provides methods for enriching, identifying, and/or quantifying unusually modified glycans (e.g., phosphorylated glycans, sulfated glycans, and/or multi-acetylated glycans). In many embodiments, methods comprise providing a glycan preparation from which sialic acids have been released; subjecting the sialidase-treated glycan preparation to a separation technique that separates glycans based on charge-to-mass ratio; and quantifying the charged products using at least one quantification standard.

Abstract: Compositions, methods and kits are described for identifying biomolecules (e.g., proteins and nucleic acids) expressed in a biological sample that are associated with the presence, development, or progression of a disease (such as cancer), or more generally determination of the etiology or risk factors associated with a disease. Sample types analyzed by the disclosed methods include but are not limited to archival tissue blocks that have been preserved in a fixative, tissue biopsy samples, tissue microarrays, and so forth. The methods disclosed herein correlate expression profiles of biomolecules with various disease types, and allow for the determination of relative survival rates; in some embodiments, the methods permit determination of survival rates for a subject with cancer. In other embodiments, the disclosure relates to methods for evaluating therapeutic regimes for the treatment, such as treatment of cancer.

Abstract: The present technology relates to methods and systems for detection of pyrophosphate. As such, disclosed herein are methods and systems that permit improved pyrophosphate detection. Also disclosed herein are methods and systems which utilize improved pyrophosphate detection for nucleotide sequencing.

Abstract: Provided are methods for detecting the presence or absence of a pathogen, disease, or medical condition, or biomarker thereof, using an enzymatic activity assay. In one embodiment, the method provided utilizes competitive inhibition of an enzyme for detecting a pathogen, disease, or medical condition, or biomarker thereof, in a subject. The method comprises providing a biological sample from the subject that may or may not contain an endogenous substrate. A test reaction is provided by contacting the biological sample with an enzyme indicative of the biomarker of a pathogen, disease, or medical condition and a substrate comprising a signaling moiety. The enzyme modifies the endogenous substrate and the substrate comprising the signaling moiety. Modification of the substrate comprising the signaling moiety by the enzyme produces a signal from the signaling moiety. Data from a control reaction comprising the enzyme and the substrate comprising the signaling moiety is further provided.

Abstract: The present invention relates to gold nanocluster compounds, especially gold nanoparticles, having a reduced toxicity, especially cytotoxicity, which are preferably appropriate for use in medical diagnostics such as medical imaging (e.g. X-ray, CT etc.), said gold nanocluster compounds comprising a core of at least one gold atom and at least one ligand bound to said core, wherein the reduction of toxicity, especially cytotoxicity, of said gold nanocluster compound is controlled and/or adjusted via its ligand structure and/or its ligand chemistry.

Abstract: The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc Such diseases and disorders include neurodegenerative diseases, tauopathy, cancers, and cardiac disorders

Abstract: The present invention relates to novel methods for screening for histone deacetylase enzyme activity in a test sample. The present invention further relates to novel methods for screening potential inhibitors of histone deacetylase enzymes.

Abstract: The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: in which n is equal to 0, 1, 2, 3 or 4; m is equal to 0, 1 or 2; o is equal to 0 or 1; X represents a group —CH2, —CH(R?)—, —NH(R?)— or a heteroatom chosen from O and S, it being understood that R? represents a group —(C1-C5)alkyl, —(C1-C5)alkoxy, —CH2-aryl, —C(O)R5 or —COOR5; R1 represents an oxo group, —COOR5, —W—OH or —W—NR5R6; R2 represents an H atom or a group chosen from the groups (i) —(C1-C5)alkyl, (ii) —(C1-C5)alkoxy, (iii) —COOR5, (iv) —NR5R6, (v) —C(O)—NR5R6, (vi) —SO2—NR3R4, (vii) heteroaryl optionally substituted with a group —(C1-C5)alkyl, (viii) —W-aryl, (ix) —W-heteroaryl, (x) —O—W-aryl, (xi) —O—W-heteroaryl and (xii) —O—W—NR5R6; it being understood that R3 and R4, (i) which may be identical or different, represent, independently of each other, an H atom, a group —(C1-C5)alkyl, —(C3-C6)cycloalkyl, aryl, heteroaryl, —CH2-heteroaryl, —(C1-C5)alkyl-NR5R6, —W—OH or —W—NR5R6; or

Abstract: The present invention relates to xyloglucanases belonging to family 44 of glycosyl hydrolases and having a relative xyloglucanase activity of at least 30% between pH 5 and pH 8 are derived from the genus Paenibacillus, especially from a strain of Paenibacillus polymyxa or Paenibacillus sp. The xyloglucanases exhibit high performance in conventional detergent compositions.

Abstract: The invention relates to compositions, systems, and methods for simultaneously detecting the presence and quantity of one or more different compounds in a sample using aptamer beacons. Aptamer beacons are oligonucleotides that have a binding region that can bind to a non-nucleotide target molecule, such as a protein, a steroid, or an inorganic molecule. New aptamer beacons having binding regions configured to bind to different target molecules can be used in solution-based and solid, array-based systems. The aptamer beacons can be attached to solid supports, e.g., at different predetermined points in two-dimensional arrays. The invention includes devices, methods, and computer software for carrying out the methods.

Abstract: The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.

Abstract: The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.

Abstract: The present disclosure provides methods for analyzing structure and/or composition of glycoproteins and glycans of glycoproteins. Such methods can include subjecting a glycoprotein preparation to a condition that removes at least one O-linked glycan from the glycoprotein. Such methods can include subjecting a glycoprotein preparation to a condition that releases an N-glycan from the glycoprotein, e.g., prior to subjecting the glycoprotein to a condition that releases an O-glycan from the glycoprotein.

Abstract: We describe a strategy for designing and implementing protein-fragment complementation assays (PCAs) to detect biomolecular interactions in vivo and in vitro. The design, implementation and broad applications of this strategy are illustrated with a large number of enzymes with particular detail provided for the example of murine dihydrofolate reductase (DHFR). Fusion peptides consisting of N- and C-terminal fragments of murine DHFR fused to GCN4 leucine zipper sequences were coexpressed in Escherichia coli grown in minimal medium, where the endogenous DHFR activity was inhibited with trimethoprim. Coexpression of the complementary fusion products restored colony formation. Survival only occurred when both DHFR fragments were present and contained leucine-zipper forming sequences, demonstrating that reconstitution of enzyme activity requires assistance of leucine zipper formation. DHFR fragment-interface point mutants of increasing severity (Ile to Val, Ala and Gly) resulted in a sequential increase in E.

Abstract: The present invention is directed to acute kidney injury biomarkers, and methods and kits comprising the use of agents directed against acute kidney injury biomarkers for facilitating and enhancing the diagnosis of AKI. The present invention is based on the discovery that specific biomarkers are present in urine at higher concentrations in subjects with acute kidney injury (AKI) as compared with subjects that have no symptoms of AKI. The invention is directed to methods for diagnosis of AKI by determining and monitoring the levels of at least one biomarker protein in a biological sample, such as urine. Further, the invention is directed to methods for facilitating the distinction of kidney infection from bladder infection in a subject.

Abstract: A plating medium for identification of Enterobacter sakazakii bacteria having a carbohydrate, but Enterobacter sakazakii bacteria being incapable of fermenting any carbohydrate in the medium. The medium also contains a pH indicator dye that changes the color of the medium from a first color to a second color when the pH changes, first and second chromogenic substrates that react to alpha-glucosidase and beta cellobiosidase enzymes, respectively, to produce a third color in the medium, and agar to solidify the mixture.

Abstract: The invention is directed to a novel enzymatic analytical membrane, a lateral flow enzymatic detection method, and analytical device incorporating same. The invention is useful for rapidly enzymatically determining the presence of one or more analytes in small volumes of sample. The invention provides an enzymatic analytical membrane for detecting the presence of one or more small-molecule analytes in a biological sample where the membrane comprises a receiving zone; a separation zone and a signal zone, at least one of the zones comprising one or more enzymes for converting the analytes into a form detectable by reaction with a chromogenic agent present in the signal zone and wherein the membrane horizontally receives sample at the receiving zone, and the sample continues via lateral flow through the receiving zone, separation zone and signal zone where a visible color change is formed indicating the presence of the analyte.

Abstract: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) in an amount sufficient to inhibit expression or activity of EIF4A, where the agent is not resveratrol.

Abstract: The present invention relates to a novel beta-galactosidase derived from Streptococcus pneumoniae, a BgaC protein exhibiting the enzyme activity, and a method for using the same. The protein can be used in the modification and analysis of sugar chain and used as an anti-cancer agent.

Abstract: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate.

Abstract: The present invention provides compositions, devices, kits, and methods for determining the risk of peri-operative cardiovascular events or predicting cardiovascular events associated with angioplasty. In certain embodiments, the present invention provides methods, compositions, kits, and devices configured for determining the value of at least two markers selected from myeloperoxidase (MPO), an F2-isoprostane (F2-IsoP), C-reactive protein (CRP), urinary micro-albumin (UMA), and lipoprotein-associated phospholipase A2 (Lp-PLAZ), such that a subject's risk of experiencing a cardiovascular event is determined.

Abstract: The invention relates to modulation of circadian rhythm and underlying biological processes.

Abstract: The present invention relates to a method for treating cancer in a subject by inhibiting DHX36, by administering to said subject a therapeutically effective amount of a modulator of DHX36.

Abstract: A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.